274 related articles for article (PubMed ID: 28546357)
41. Antihypertensives and Antibiotics: Impact on Intestinal Dysfunction and Hypertension.
Lucas SE; Walton SL; Mirabito Colafella KM; Mileto SJ; Lyras D; Denton KM
Hypertension; 2023 Jul; 80(7):1393-1402. PubMed ID: 37039016
[TBL] [Abstract][Full Text] [Related]
42. Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease.
Mouzaki M; Bandsma R
Curr Drug Targets; 2015; 16(12):1324-31. PubMed ID: 25882223
[TBL] [Abstract][Full Text] [Related]
43. Microbial Interactions and Interventions in Colorectal Cancer.
Van Raay T; Allen-Vercoe E
Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643625
[TBL] [Abstract][Full Text] [Related]
44. A Review on Gut Remediation of Selected Environmental Contaminants: Possible Roles of Probiotics and Gut Microbiota.
Feng P; Ye Z; Kakade A; Virk AK; Li X; Liu P
Nutrients; 2018 Dec; 11(1):. PubMed ID: 30577661
[TBL] [Abstract][Full Text] [Related]
45. The role of probiotics on each component of the metabolic syndrome and other cardiovascular risks.
Miglioranza Scavuzzi B; Miglioranza LH; Henrique FC; Pitelli Paroschi T; Lozovoy MA; Simão AN; Dichi I
Expert Opin Ther Targets; 2015; 19(8):1127-38. PubMed ID: 25872805
[TBL] [Abstract][Full Text] [Related]
46. Intersection of salt- and immune-mediated mechanisms of hypertension in the gut microbiome.
Wyatt CM; Crowley SD
Kidney Int; 2018 Mar; 93(3):532-534. PubMed ID: 29475542
[No Abstract] [Full Text] [Related]
47. Microbial modulation of the gut microbiome for treating autoimmune diseases.
Balakrishnan B; Taneja V
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):985-996. PubMed ID: 30146910
[TBL] [Abstract][Full Text] [Related]
48. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.
Oh B; Kim BS; Kim JW; Kim JS; Koh SJ; Kim BG; Lee KL; Chun J
Helicobacter; 2016 Jun; 21(3):165-74. PubMed ID: 26395781
[TBL] [Abstract][Full Text] [Related]
49. Gut microbiota, hypertension and chronic kidney disease: Recent advances.
Sircana A; De Michieli F; Parente R; Framarin L; Leone N; Berrutti M; Paschetta E; Bongiovanni D; Musso G
Pharmacol Res; 2019 Jun; 144():390-408. PubMed ID: 29378252
[TBL] [Abstract][Full Text] [Related]
50. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
[TBL] [Abstract][Full Text] [Related]
51. Gut microbiota and bacterial translocation in digestive surgery: the impact of probiotics.
Komatsu S; Yokoyama Y; Nagino M
Langenbecks Arch Surg; 2017 May; 402(3):401-416. PubMed ID: 28321508
[TBL] [Abstract][Full Text] [Related]
52. Gut microbiota in autoimmunity: potential for clinical applications.
Kim D; Yoo SA; Kim WU
Arch Pharm Res; 2016 Nov; 39(11):1565-1576. PubMed ID: 27444041
[TBL] [Abstract][Full Text] [Related]
53. Altered microRNA regulation of short chain fatty acid receptors in the hypertensive kidney is normalized with hydrogen sulfide supplementation.
Weber GJ; Foster J; Pushpakumar SB; Sen U
Pharmacol Res; 2018 Aug; 134():157-165. PubMed ID: 29909116
[TBL] [Abstract][Full Text] [Related]
54. Gut-Brain Axis and Stress Regulation: Effects of Probiotics on Neurocognition.
Ross SM
Holist Nurs Pract; 2019; 33(5):312-315. PubMed ID: 31415011
[No Abstract] [Full Text] [Related]
55. Gut microbiota and the pathogenesis of necrotizing enterocolitis in preterm neonates.
Cassir N; Simeoni U; La Scola B
Future Microbiol; 2016; 11(2):273-92. PubMed ID: 26855351
[TBL] [Abstract][Full Text] [Related]
56. Antihypertensive activity of blueberries fermented by Lactobacillus plantarum DSM 15313 and effects on the gut microbiota in healthy rats.
Ahrén IL; Xu J; Önning G; Olsson C; Ahrné S; Molin G
Clin Nutr; 2015 Aug; 34(4):719-26. PubMed ID: 25194632
[TBL] [Abstract][Full Text] [Related]
57. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
[TBL] [Abstract][Full Text] [Related]
58. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
[TBL] [Abstract][Full Text] [Related]
59. The developing gut microbiota and its consequences for health.
Butel MJ; Waligora-Dupriet AJ; Wydau-Dematteis S
J Dev Orig Health Dis; 2018 Dec; 9(6):590-597. PubMed ID: 29562949
[TBL] [Abstract][Full Text] [Related]
60. Gut microbiota and inflammatory bowel disease: so far so gut!
Holleran G; Lopetuso LR; Ianiro G; Pecere S; Pizzoferrato M; Petito V; Graziani C; McNAMARA D; Gasbarrini A; Scaldaferri F
Minerva Gastroenterol Dietol; 2017 Dec; 63(4):373-384. PubMed ID: 28293937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
